Aldosterone synthase inhibition in mineralocorticoid blockade: From hypertension to cardiovascular and kidney disease.

The Advance-HTN trial demonstrated that lorundrostat, an aldosterone synthase inhibitor, effectively reduced 24-h systolic blood pressure by 8 mm Hg in resistant hypertension, with manageable hyperkalemia.1 These findings support further research into aldosterone synthase inhibitors as promising alternatives to mineralocorticoid receptor antagonists for resistant hypertension management.